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Abstract
Background
Studies of the functional consequences of DCM-causing mutations have been limited to a
few cases where patients with known mutations had heart transplants. To increase the num-
ber of potential tissue samples for direct investigation we performed whole exon sequencing
of explanted heart muscle samples from 30 patients that had a diagnosis of familial dilated
cardiomyopathy and screened for potentially disease-causing mutations in 58 HCM or
DCM-related genes.
Results
We identified 5 potentially disease-causingOBSCNmutations in 4 samples; one sample
had twoOBSCNmutations and one mutation was judged to be not disease-related. Also
identified were 6 truncating mutations in TTN, 3 mutations inMYH7, 2 in DSP and one each
in TNNC1, TNNI3,MYOM1, VCL, GLA, PLB, TCAP, PKP2 and LAMA4. The mean level of
obscurin mRNA was significantly greater and more variable in healthy donor samples than
the DCM samples but did not correlate with OBSCNmutations. A single obscurin protein
band was observed in human heart myofibrils with apparent mass 960 ± 60 kDa. The three
samples with OBSCNmutations had significantly lower levels of obscurin immunoreactive
material than DCM samples without OBSCNmutations (45±7, 48±3, and 72±6% of control
level).Obscurin levels in DCM controls, donor heart and myectomy samples were the same.
Conclusions
OBSCNmutations may result in the development of a DCM phenotype via haploinsuffi-
ciency. Mutations in the obscurin gene should be considered as a significant causal factor
of DCM, alone or in concert with other mutations.
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Introduction
Dilated Cardiomyopathy is a common disease of the myocardium characterised by dilated ven-
tricles and impaired contractility in the absence of any apparent cause, such as coronary artery
disease, myocardititis, hypertension, hypertrophic cardiomyopathy or valve disease[1]. Dilated
cardiomyopathy frequently leads to heart failure that requires heart transplant.
It is estimated that at least 40% of DCM cases are inherited. Mutations in over 50 genes
have been associated with familial DCM, mostly encoding sarcomeric, Z disc and costamere
proteins [2]. Truncating mutations in the TTN gene have recently been demonstrated to be the
most common cause of FDCM, being identified in around 25% of cases [3, 4]. Studies of the
functional consequences of DCM-causing mutations have been limited to a few cases where
patients with known mutations had heart transplants [5]. In order to increase the number of
potential tissue samples for direct investigation we performed whole exon sequencing of
explanted heart muscle samples from 30 patients in the Sydney Heart Bank that had a diagnosis
of familial dilated cardiomyopathy. We found potential disease-causing variants in 23 of the
patients, mostly in the known DCM-associated genes, including 6 titin truncating mutations.
In addition we found 3 mutations in the OBSCN gene that codes for obscurin that suggest this
may be a significant cardiomyopathy-associated gene.
Obscurin is a component of the sarcomere that is found bound near the M-line or Z-disk. It
has been shown to interact with titin, myomesin and small ankyrin1 and has been proposed to
be a structural protein linking the M-line of the sarcomere to the sarcoplasmic reticulum[6–9].
Little is known of it role in the heart: it is reported to be up-regulated in hypertrophic heart
[10] but an obscurin knockout mouse exhibited only mild myopathy [11]. Only one mutation
in OBSCN has been reported associated with cardiomyopathy; Arimura et al found
Arg4344Gln to be related to hypertrophic cardiomyopathy [12]. OBSCN mutations have not
previously been reported associated with dilated cardiomyopathy, however, obscurin is
expressed in a range of alternatively spliced isoforms in most tissues and OBSCN mutations
have been associated with several types of cancer [13, 14].
In this manuscript we have identified OBSCN mutations potentially associated with dilated
cardiomyopathy and have investigated the properties of the heart muscles containing OBSCN
mutations. We have found that Obscurin expression levels are abnormal when OBSCN is
mutated.
Materials and Methods
We used tissue samples from explanted hearts in the Sydney Heart bank (listed in Supplement
A). 30 patients with a diagnosis of familial DCM or idiopathic DCM requiring transplant at a
young age were selected for sequencing and further studies. As controls we studied muscle
from 6 donor hearts and 3 myectomy samples from patients with HCM (Fig B in S1 File).
Donor hearts had no history of cardiac disease and normal ECG and ventricular function and
were obtained when no suitable transplant recipient was found. Ethical approval was granted
by the Research Integrity, Human Research Ethics Committee, University of Sydney (Protocol
No 15401) for collection and distribution of the human heart samples and by the NHS
National Research Ethics Service, South West London REC3 (10/H0803/147) for study of the
samples. Patients gave written consent with PIS approved by the relevant ethical committee.
All samples are anonymised. The investigations conform to the principles of the Declaration of
Helsinki. The functional characteristics of some of the donor heart and myectomy samples
have been previously reported.[15, 16].
For the genetic investigations we studied a control cohort of patients previously treated with
doxorubicin who did not develop heart failure, as previously described [17].
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cardiomyopathy; q-RT-PCR, quantitative reverse
transcriptase polymerase chain reaction; SDS-PAGE,
sodium dodecyl sulphate polyacrylamide gel
electrophoresis; LVEF, left ventricular ejection
fraction; LVEDD, left ventricular end-diastolic
diameter; LVESD, left ventricular end-systolic
diameter; FS, fractional shortening; IHD, ischemic
heart disease; CAD, coronary artery disease; EVS,
Exon Variants Server; ESE_GAIN, gain of a new
exonic splice enhancer element; ESE_LOSS, loss of
a exonic splice enhancer element;
ESE2ESS_CHANGE, an exonic enhancer element
changes into a silencer element.
DNA extraction, whole exome sequencing, pyrosequencing, RNA extraction, q-RT-PCR,
SDS-PAGE electrophoresis, western blotting and immunofluorescence microscopy were per-
formed by standard methods described in the supplemental methods in S1 File. Obscurin
sequences determined were compared with the canonical Obscurin B sequence: RefSeq
NP_001092093 and UniProt Q5VST9.
Results
We studied muscle samples from 30 explanted hearts of patients with end-stage heart failure
and a diagnosis of familial dilated cardiomyopathy. Whole exon sequence data from the patient
cardiac muscle samples was screened for potentially disease-causing variants in 58 genes previ-
ously implicated in HCM or DCM (Fig C in S1 File). The initial screen identified 5 OBSCN
variants in 4 samples (D4, D14, D20 and D21; D14 contained 2 OBSCN variants, Fig 1).
Also identified were 6 truncating mutations in TTN, 3 mutations in MYH7, 2 in DSP and
one each in TNNC1, TNNI3, MYOM1, VCL, GLA, PLB, TCAP, PKP2 and LAMA4 (Fig A in S1
File). The sequencing confirms mutations in TNNC1 (D1) and TNNI3 (D2) that have been pre-
viously studied [5, 18]. In addition to the OBSCNmutations, D4 also had a DSP mutation and
D21 also had a SCN5Amutation. The OBSCNmutations were confirmed by pyrosequencing.
In the “1000 genomes” database one of the mutations in D14 (pF2809V) was found to be
present in 14% of genomes and once in our 450 control samples but the other variants were
absent. In the Exome Variant Server database, that includes both normal and pathological
Fig 1. Clinical and genetic data of the 4 heart samples with potentially disease-causingOBSCNmutations. The locations of the mutations in the
Obscurin B domain diagram are shown, based on the model of Ackerman et al. 2014 (ref 14) (Fig E in S1 File)
doi:10.1371/journal.pone.0138568.g001
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genomes, both the mutations in D14 were found (pV2161D at 0.03% and pF2809V at 0.08%)
and the mutation in D21 was found at 0.2%. All the missense mutations affect fully conserved
residues in OBSCN (Fig D in S1 File) except for D21. We therefore excluded D21 as a potential
disease-causing mutation.
We investigated the expression of obscurin in the myofibrillar fraction of human heart mus-
cle samples. The obscurin protein band was barely visible on SYPRO-ruby stained SDS-PAGE
gels. Obscurin was positively identified in Western blots using antibodies to domains 13, 58
and 59 ([8], Fig E in S1 File); all three antibodies produced similar results. Obscurin had an
apparent mass of around 963±64kDa based on its migration distance on 2% agarose/2% poly-
acrylamide SDS-PAGE calibrated with titin and Myosin heavy chain. No lower molecular
weight peptides were detected in any samples with any antibody. DCM samples with obscurin
mutations were indistinguishable from DCM samples without obscurin mutations and donor
heart samples on Western blots (Fig 2). The obscurin band in the myofibrillar fraction was
quantified on SDS-PAGE relative to α-actinin in the same lane (Fig 3).
Obscurin mutants D4, D14 and D20 exhibited significantly lower levels of obscurin protein
compared with the other DCM samples and controls (D4, 45±7%, p =<0.0001, n = 8, D14, 48
±3%, p =<0.0001, n = 21 and D20, 72±6%, p =<0.014, n = 14). The level of obscurin in myofi-
brils was not significantly different between donor, DCM (no OBSCNmutation) and HCM
(myectomy) controls.
Fig 2. Analysis of obscurin protein expression in tissue samples. Left: Identification of obscurin in cardiac myofibrils by 2% agarose/2% PAA/SDS gel
electrophoresis. Left, SYPRORuby protein stain, Right Western blot Ob59 antibody. Centre: Obscurin expression in myofibrils. Western blot of 4–18%
gradient SDS-PAGE. Left: membrane stained with MemCode protein stain, right: probed with Ob59 antibody. For quantification obscurin was normalised to
α-actinin. Right: Identification of obscurin in whole heart muscle homogenates. Top, MemCode protein stain; bottom, Western blot with Ob59 antibody.
doi:10.1371/journal.pone.0138568.g002
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In heart muscle homogenates multiple isoforms of Obscurin were detected, notably at 960,
420 and 250kDa (Fig 2C). Quantification of the total obscurin (sum of 960,420 and 250kDa
bands) revealed substantial obscurin haploinsufficiency in all the Obscurin mutant samples rel-
ative to donor heart (Fig G in S1 File). The relative quantities of the three bands was not signifi-
cantly different between donor and obscurin mutant-containing heart muscle samples, but we
noted an interesting regional variation of the proportions of obscurin isoforms. D16 –D30 are
atrial samples whilst the D1–D15 and donor and myectomy controls are from left ventricle; we
noted that atrial muscle contained significantly more 963kDa band (60.3±5.1%) and less
250kDa band than ventricular tissue (34.3±4.9%, p = 0.00033) (Fig G in S1 File)
We measured obscurin mRNA expression in the cardiomyopathy tissue samples and in
controls. The expression of obscurin mRNA is low (ratio =< 0.03) compared to the expression
Fig 3. Quantification of Obscurin content of human cardiac myofibrils. A. 4–18% SDS-PAGE of muscle myofibril fraction. Western blot reversibly
stained for total protein by MemCode and then probed with Obscurin antibody Ob59. Obscurin band is normalized to the α-actinin band as a loading control
and further normalized to D21, present in every slab gel to control for inter-gel variation. B. Relative obscurin protein level normalised to D21. D4, D14, and
D20 are compared with 7 DCM samples without obscurin mutations, 6 donor heart samples and 3 myectomy samples (described in S1 File Figs A, B). Data
from 22 slab gels similar to that in 2A pooled. The bars represent sem for replicate measurements on the same sample.
doi:10.1371/journal.pone.0138568.g003
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of GAPDH in all samples and variable between the DCM samples and donor heart or HCM
heart (myectomy) samples used as control (Fig F in S1 File). When normalised, the mean level
of obscurin mRNA was significantly greater and more variable in donor samples than the
DCM samples, however the obscurin mRNA content of DCM samples with obscurin muta-
tions was not significantly different from the DCMmutations without obscurin mutations.
Finally, we studied the human tissue samples by immunofluorescence microscopy using
obscurin, myomesin (M line) and α-actinin (z-disc)-specific antibodies (Fig 4). These clearly
showed that obscurin was located at the level of the M-line, coincident with the myomesin
label and complementary to the α-actinin (z-disc) label. We could not detect any consistent dif-
ference in obscurin quantity or location between samples containing obscurin mutations and
donor heart samples.
Discussion
Whole exome sequencing of explanted heart samples from 30 selected patients with end-stage
heart failure, most of which were diagnosed with familial DCM, revealed 26 potentially dis-
ease-causing variants in 14 genes, 10 of which have been previously reported ((Fig A in S1
File). This finding of many potentially disease causing mutations in end-stage DCM patients in
our small sample correlates with Roberts et al finding in a large population that TTN trunca-
tion mutations had a>96% probability of pathogenicity when found in end-stage DCM
patients [4].
In addition to the known cardiomyopathy-causing genes, we found 4 novel potentially dis-
ease-causing variants in the OBSCN gene (Fig 1). This frequency is unexpectedly high since
OBSCN mutations have only rarely been linked with any cardiomyopathy. One mutation has
been described associated with HCM (in domain 58) and several associated with various forms
of cancer[12, 19]. This is thus the first description of an association between OBSCN mutations
and dilated cardiomyopathy. We have also investigated obscurin protein levels and have estab-
lished that the OBSCNmutations are associated with reduced obscurin expression levels,
which points to haploinsufficiency as a possible disease causing mechanism.
15% of the potentially disease-causing variants identified in our samples, were in the
OBSCN gene; this frequency is similar to that found for TTN truncating mutations that have
been proposed as the major gene associated with DCM [4]. Thus, OBSCNmutations may also
be significant contributors to DCM burden. The reason why OBSCNmutations have not been
detected before is probably because the large size of the gene has precluded investigation.
One of the variants (D20) was not found in any control population (Fig 1). This mutation is
located in the PH domain of obscurin that has been proposed to interact with RhoA. D14 con-
tained two variants in OBSCN, one of which (F2809V) was present at 14% in the 1000 genomes
database and lower frequencies in the Exon Variants Server (EVS) and our cohort of 460 cancer
patients; the other (V2161D) was found at a low frequency in the EVS database only; there is
no evidence that the two mutations in D14 have been found together before. It is noted that D4
also contained the DSP variant p.R1537C, which was excluded as a disease-causing mutation
previously [20]. Mutations in D4 and D14 are in Ig domains with no documented interaction
with other proteins. The D21 OBSCNmutation is considered not disease-causing since the
affected amino-acid is not conserved between species and the mutation is present in control
populations; moreover, this sample also contains the SCN5Amutation p.S216L, which has
been linked to Brugada syndrome[21] and may be a more likely cause of the end-stage heart
failure in this patient.
Little is known about obscurin in human heart muscle. When we tested the expression of
obscurin in the myofibril fraction of human heart tissue samples we found that Obscurin was
OBSCNMutations and Dilated Cardiomyopathy
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Fig 4. Immunofluorescence images of donor andOBSCNmutation- containing human heart tissue
sections labelled with Ob59 antibody (green) and anti- α-actinin or anti-myomesin (red). The
monochrome panels show the obscurin immunofluorescence on its own.
doi:10.1371/journal.pone.0138568.g004
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present as a single band in all samples with an apparent molecular mass of 960kDa, equivalent
to the Obscurin B isoform although smaller, presumably non-muscle, isoforms were observed
in the cytoplasm [14]. OBSCN variants D4, D14 and D20 were associated with haploinsuffi-
ciency in the myofibrillar fraction, with obscurin expression in the range 45–72% of the con-
trols (Fig 3). and this was also apparent in whole tissue (Fig G in S1 File). Parallel
measurements of the titin content in the heart samples with titin truncating mutations (Fig A
in S1 File) did not show any evidence of titin haploinsufficiency in agreement with [4]. Hap-
loinsufficiency has not previously been reported as a significant factor in DCM but it has been
observed in HCM: haploinsufficiency of up to 25% has been shown to be common inMYBPC3
mutations that cause HCM [22, 23]. Nonsense-mediated mRNA decay and degradation of pro-
tein via the ubiquitin-proteasome system have been suggested as major pathways for haploin-
sufficiency [24], however the mRNA measurements did not provide any evidence for a
mutation-related decrease in total obscurin mRNA (Fig F in S1 File). Obscurin is bound to the
myofibril through titin and myomesin, and to the sarcoplasmic reticulum through small
ankyrin-1[8, 25], consistent with its location at the M-line (Fig 4). Weakening of obscurin
binding to the myofibril could cause the observed reduced obscurin content, however this is
unlikely to be the cause of the reduced obscurin content of myofibrils since obscurin was also
less abundant in whole tissue extract (Fig G in S1 File). Moreover, we did not detect any reduc-
tion or relocation of obscurin associated with the mutations by immunofluorescence micros-
copy (Fig 4).
Conclusion
We have identified OBSCN as a new human cardiomyopathy gene and mutations in this gene
should be considered as a significant cause of DCM alone or in concert with another mutation.
Disease-related OBSCN mutations cause haploinsufficiency that could account for the devel-
opment of a DCM phenotype and merit further investigation.
Supporting Information
S1 File. A. Table of muscle samples studied and putative disease-causing mutations found. B.
Patient data for the donor heart muscle used as controls in this study. C. WES sequencing pro-
tocols: left, list of genes tested for mutations, right filter conditions used to find the potential
disease-causing mutations. D. Alignment of Obscurin B isoforms in human, mouse, mole rat
and turtle. Only the regions of the sequence with mutations are shown. E. Domain diagram of
the two large muscle isoforms of obscurin. Location of mutations and the epitopes of Ob13,
Ob58 and Ob59 are shown. F. Relative Obscurin mRNA content of heart muscle samples nor-
malised to GAPDHmRNA. G. Relative obscurin protein expressed in whole homogenates of
heart muscle. A) Western blots of whole heart muscle homogenates separated by SDS- PAGE
(See Fig 2). Top Memcode protein stain, bottom Ob59 anti-obscurin antibody. B) Calculated
relative obscurin levels using the method as shown in Fig 3. Results from individual lanes are
shown. C) Relative proportions of the three obscurin bands in atrial and ventricular muscle
homogenates.
(PDF)
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